<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310554</url>
  </required_header>
  <id_info>
    <org_study_id>M2017187</org_study_id>
    <nct_id>NCT03310554</nct_id>
  </id_info>
  <brief_title>Suspended Overlength Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture</brief_title>
  <official_title>Prevention of Duodenobiliary Reflux Via Suspended Overlength Biliary Stents in Patients With Biliary Stricture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic insertion of plastic or metal stents in bile duct under endoscopic retrograde&#xD;
      cholangiopancreatography is a well established treatment of distal malignant biliary&#xD;
      obstruction.Biliary stents are widely used to relieve symptoms of malignant biliary&#xD;
      stricture.Now, the mainly used biliary stents include plastic and metal stents. The main&#xD;
      limitation of long time plastic stents is stents occlusion. Biliary plastic stents are&#xD;
      changed every 2 to 3 months due to an expected median patency from 77 to 126 days.Metal&#xD;
      stents present a lower risk of recurring biliary occlusion, yet high cost and stents&#xD;
      occlusion are eventually inevitable. The mechanism of biliary stents occlusion include&#xD;
      biliary sluge of the accumulation of bacteria and duodenal biliary reflux .The anti-reflux&#xD;
      barrier of Oddi's sphincter disappears after the insertion of biliary stents and the presure&#xD;
      in bile duct lowers the duodenals, which cause the retrograde flow of duodenal material into&#xD;
      the biliary ducts. Besides, ordinary biliary plastic stent is short which can also shortens&#xD;
      the length of duodenal biliary reflux . Therefore, trying to prevent the duodenal biliary&#xD;
      reflux is very important in reducing biliary stents occlusion and it is gradually concerned&#xD;
      by clinical researchers. Some studies have showed that plastic stents with antireflux valves&#xD;
      can effectively reduce the biliary stent stricture and prolong the stents patency, which&#xD;
      means reducing duodenobiliary reflux is surely useful for keeping biliary stent patency.So,we&#xD;
      assume to explore an innovatively suspended overlength biliary stents (made from nasobiliary&#xD;
      tube with length of 26cm or 30cm) as substitution for ordinary biliary plastic stent to&#xD;
      prevent the duodenobiliary reflux by extending the length of duodenal content reflux and&#xD;
      avoid the stents shift via suspending in intrahepatic duct. In this study,we will design a&#xD;
      randomized controlled trial to compare the patency of different length of suspended&#xD;
      overlength biliary stents and ordinary plastic biliary stents in patients with distal&#xD;
      malignant biliary obstruction to evaluate the effect and safety of suspended overlength&#xD;
      biliary stents for the prevention of duodenobiliary reflux and the effect of different length&#xD;
      of the stents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic insertion of plastic or metal stents in bile duct under endoscopic retrograde&#xD;
      cholangiopancreatography is a well established treatment of distal malignant biliary&#xD;
      obstruction.Biliary stents are widely used to relieve symptoms of malignant biliary&#xD;
      stricture.Now, the mainly used biliary stents include plastic and metal stents. The main&#xD;
      limitation of long time plastic stents is stents occlusion. Biliary plastic stents are&#xD;
      changed every 2 to 3 months due to an expected median patency from 77 to 126 days.Metal&#xD;
      stents present a lower risk of recurring biliary occlusion, yet high cost and stents&#xD;
      occlusion are eventually inevitable. The mechanism of biliary stents occlusion include&#xD;
      biliary sluge of the accumulation of bacteria and duodenal biliary reflux .The anti-reflux&#xD;
      barrier of Oddi's sphincter disappears after the insertion of biliary stents and the presure&#xD;
      in bile duct lowers the duodenals, which cause the retrograde flow of duodenal material into&#xD;
      the biliary ducts. Besides, ordinary biliary plastic stent is short which can also shortens&#xD;
      the length of duodenal biliary reflux . Therefore, trying to prevent the duodenal biliary&#xD;
      reflux is very important in reducing biliary stents occlusion and it is gradually concerned&#xD;
      by clinical researchers. Some studies have showed that plastic stents with antireflux valves&#xD;
      can effectively reduce the biliary stent stricture and prolong the stents patency, which&#xD;
      means reducing duodenobiliary reflux is surely useful for keeping biliary stent patency&#xD;
      .So,we assume to explore an innovatively suspended overlength biliary stents (made from&#xD;
      nasobiliary tube with length of 26cm or 30cm) as substitution for ordinary biliary plastic&#xD;
      stent to prevent the duodenobiliary reflux by extending the length of duodenal content reflux&#xD;
      and avoid the stents shift via suspending in intrahepatic duct. In this study,we will design&#xD;
      a randomized controlled trial to compare the patency of different length of suspended&#xD;
      overlength biliary stents and ordinary plastic biliary stents in patients with distal&#xD;
      malignant biliary obstruction to evaluate the effect and safety of suspended overlength&#xD;
      biliary stents for the prevention of duodenobiliary reflux and the effect of different length&#xD;
      of the stents.&#xD;
&#xD;
      The investigators will recruit patients according to admission criteria and exclusion&#xD;
      criteria. Eligible patients with distal malignant biliary obstruction will be randomly&#xD;
      divided into 26cm suspended overlength biliary stents group (experimental group) „ÄÅ30cm&#xD;
      suspended overlength biliary stents group (experimental group) and ordinary plastic biliary&#xD;
      stents group (control group).The test groups will be placed the 26cm or 30cm suspended&#xD;
      overlength biliary stents in introhepatic bile duct in ERCP. The control group will be placed&#xD;
      ordinary plastic biliary stents in ERCP. The primary endpoint is the duration of stent&#xD;
      patency and the rate of stent occlusion.The secondary outcomes include the mortality of each&#xD;
      group, adverse events and the rate of technical success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinding of endoscopists and patients is impossible.But the endoscopists are not involved in the assessment of outcomes. The outcomes assessments are performed by reviewing physicians blinded to the randomization process. The data manager and statistician are not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>stent patency and stent occlusion rate</measure>
    <time_frame>12 months after ERCP</time_frame>
    <description>Patients with symptoms of cholangitis and worsening liver function tests suggestive of cholestasis are considered as premature stent occlusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality of each group</measure>
    <time_frame>12 months after ERCP</time_frame>
    <description>We will compare the mortality of each group after the insertion of biliary stents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months after ERCP</time_frame>
    <description>Adverse events include complications of post ERCP such as pancreatitis,biliary infection, bleeding, perforation and stent migration etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of technical success</measure>
    <time_frame>12 months after ERCP</time_frame>
    <description>Technical success is defined as successful insertion of the stent into the bile duct during ERCP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Bile Duct Stricture</condition>
  <arm_group>
    <arm_group_label>26cm suspended overlength biliary stents group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30cm suspended overlength biliary stents group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ordinary plastic biliary stents group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>26cm suspended overlength biliary stents</intervention_name>
    <description>The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP</description>
    <arm_group_label>26cm suspended overlength biliary stents group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>30cm suspended overlength biliary stents</intervention_name>
    <description>The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP</description>
    <arm_group_label>30cm suspended overlength biliary stents group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ordinary plastic biliary stents</intervention_name>
    <description>The control group will be placed ordinary plastic biliary stents in bile duct in ERCP</description>
    <arm_group_label>ordinary plastic biliary stents group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable extrahepatic malignant biliary stricture,available for insertion of&#xD;
             biliary stents in ERCP to alleviate biliary stricture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients agree with metal biliary stents;&#xD;
&#xD;
          2. Patients with biliary stricture need double or multiple stents inserted;&#xD;
&#xD;
          3. Patients with previous surgical drainage procedure;&#xD;
&#xD;
          4. Patients with resectable biliary occlusion;&#xD;
&#xD;
          5. A guidewire could not be passed through the stricture;&#xD;
&#xD;
          6. Patients with duodenal obstruction and duodenal endoscopy could not be reached to&#xD;
             papillary.;&#xD;
&#xD;
          7. Patients with any contraindication to endoscopic procedures or refuse informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yonghui Huang, archiater</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonghui Huang, archiater</last_name>
    <phone>13911765322</phone>
    <email>xuxiao_1028@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghui Huang, archiater</last_name>
      <phone>13911765322</phone>
      <email>xuxiao_1028@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Dumonceau JM, Tringali A, Blero D, Devi√®re J, Laugiers R, Heresbach D, Costamagna G; European Society of Gastrointestinal Endoscopy. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012 Mar;44(3):277-98. doi: 10.1055/s-0031-1291633. Epub 2012 Feb 1.</citation>
    <PMID>22297801</PMID>
  </results_reference>
  <results_reference>
    <citation>Libby ED, Leung JW. Prevention of biliary stent clogging: a clinical review. Am J Gastroenterol. 1996 Jul;91(7):1301-8. Review.</citation>
    <PMID>8677983</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen FM, Lassen AT, Schaffalitzky de Muckadell OB. Randomized trial of stent placed above and across the sphincter of Oddi in malignant bile duct obstruction. Gastrointest Endosc. 1998 Dec;48(6):574-9.</citation>
    <PMID>9852446</PMID>
  </results_reference>
  <results_reference>
    <citation>van Berkel AM, Boland C, Redekop WK, Bergman JJ, Groen AK, Tytgat GN, Huibregtse K. A prospective randomized trial of Teflon versus polyethylene stents for distal malignant biliary obstruction. Endoscopy. 1998 Oct;30(8):681-6.</citation>
    <PMID>9865556</PMID>
  </results_reference>
  <results_reference>
    <citation>van Berkel AM, Bruno MJ, Bergman JJ, van Deventer SJ, Tytgat GN, Huibregtse K. A prospective randomized study of hydrophilic polymer-coated polyurethane versus polyethylene stents in distal malignant biliary obstruction. Endoscopy. 2003 Jun;35(6):478-82.</citation>
    <PMID>12783344</PMID>
  </results_reference>
  <results_reference>
    <citation>Reddy DN, Banerjee R, Choung OW. Antireflux biliary stents: are they the solution to stent occlusions? Curr Gastroenterol Rep. 2006 Apr;8(2):156-60. Review.</citation>
    <PMID>16533479</PMID>
  </results_reference>
  <results_reference>
    <citation>van Berkel AM, van Marle J, van Veen H, Groen AK, Huibregtse K. A scanning electron microscopic study of biliary stent materials. Gastrointest Endosc. 2000 Jan;51(1):19-22.</citation>
    <PMID>10625789</PMID>
  </results_reference>
  <results_reference>
    <citation>Soehendra N, Reynders-Frederix V. Palliative bile duct drainage - a new endoscopic method of introducing a transpapillary drain. Endoscopy. 1980 Jan;12(1):8-11.</citation>
    <PMID>7353562</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagh MS, de Bellis M, Fogel EL, Frakes JT, Johanson JF, Qaseem T, Howell DA, Lehman GA, Sherman S. Multicenter Randomized Trial of 10-French versus 11.5-French Plastic Stents for Malignant Biliary Obstruction. Diagn Ther Endosc. 2013;2013:891915. doi: 10.1155/2013/891915. Epub 2013 May 2.</citation>
    <PMID>23737656</PMID>
  </results_reference>
  <results_reference>
    <citation>Groen AK, Out T, Huibregtse K, Delzenne B, Hoek FJ, Tytgat GN. Characterization of the content of occluded biliary endoprostheses. Endoscopy. 1987 Mar;19(2):57-9.</citation>
    <PMID>3106022</PMID>
  </results_reference>
  <results_reference>
    <citation>Speer AG, Cotton PB, Rode J, Seddon AM, Neal CR, Holton J, Costerton JW. Biliary stent blockage with bacterial biofilm. A light and electron microscopy study. Ann Intern Med. 1988 Apr;108(4):546-53.</citation>
    <PMID>2450501</PMID>
  </results_reference>
  <results_reference>
    <citation>Leung JW, Ling TK, Kung JL, Vallance-Owen J. The role of bacteria in the blockage of biliary stents. Gastrointest Endosc. 1988 Jan-Feb;34(1):19-22.</citation>
    <PMID>3280393</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu YF, Saccone GT, Thune A, Baker RA, Harvey JR, Toouli J. Sphincter of Oddi regulates flow by acting as a variable resistor to flow. Am J Physiol. 1992 Nov;263(5 Pt 1):G683-9.</citation>
    <PMID>1443142</PMID>
  </results_reference>
  <results_reference>
    <citation>Sung JY, Leung JW, Shaffer EA, Lam K, Olson ME, Costerton JW. Ascending infection of the biliary tract after surgical sphincterotomy and biliary stenting. J Gastroenterol Hepatol. 1992 May-Jun;7(3):240-5.</citation>
    <PMID>1611012</PMID>
  </results_reference>
  <results_reference>
    <citation>Donelli G, Guaglianone E, Di Rosa R, Fiocca F, Basoli A. Plastic biliary stent occlusion: factors involved and possible preventive approaches. Clin Med Res. 2007 Mar;5(1):53-60. Review.</citation>
    <PMID>17456835</PMID>
  </results_reference>
  <results_reference>
    <citation>van Berkel AM, van Marle J, Groen AK, Bruno MJ. Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. Endoscopy. 2005 Aug;37(8):729-34.</citation>
    <PMID>16032491</PMID>
  </results_reference>
  <results_reference>
    <citation>Dua KS, Reddy ND, Rao VG, Banerjee R, Medda B, Lang I. Impact of reducing duodenobiliary reflux on biliary stent patency: an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. Gastrointest Endosc. 2007 May;65(6):819-28. Epub 2007 Mar 26.</citation>
    <PMID>17383650</PMID>
  </results_reference>
  <results_reference>
    <citation>Vihervaara H, Gr√∂nroos JM, Hurme S, Gullichsen R, Salminen P. Antireflux Versus Conventional Plastic Stent in Malignant Biliary Obstruction: A Prospective Randomized Study. J Laparoendosc Adv Surg Tech A. 2017 Jan;27(1):53-57. doi: 10.1089/lap.2016.0178. Epub 2016 Oct 18.</citation>
    <PMID>27754790</PMID>
  </results_reference>
  <results_reference>
    <citation>Rees EN, Tebbs SE, Elliott TS. Role of antimicrobial-impregnated polymer and Teflon in the prevention of biliary stent blockage. J Hosp Infect. 1998 Aug;39(4):323-9.</citation>
    <PMID>9749404</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang F, Ren Z, Chai Q, Cui G, Jiang L, Chen H, Feng Z, Chen X, Ji J, Zhou L, Wang W, Zheng S. A novel biliary stent coated with silver nanoparticles prolongs the unobstructed period and survival via anti-bacterial activity. Sci Rep. 2016 Feb 17;6:21714. doi: 10.1038/srep21714.</citation>
    <PMID>26883081</PMID>
  </results_reference>
  <results_reference>
    <citation>Kenawy el-R, Abdel-Hay FI, el-Raheem A, el-Shanshoury R, el-Newehy MH. Biologically active polymers: synthesis and antimicrobial activity of modified glycidyl methacrylate polymers having a quaternary ammonium and phosphonium groups. J Control Release. 1998 Jan 2;50(1-3):145-52.</citation>
    <PMID>9685881</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Huang Yonghui</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

